You have accessJournal of UrologyCME1 Apr 2023MP08-16 COMPARISON OF INTRAVESICAL THERAPY AND SURGERY AS TREATMENT OPTIONS FOR RECURRENT BLADDER CANCER (CISTO): COLLECTION OF PATIENT-REPORTED OUTCOMES John Gore, Erika Wolff, Michael Nash, Bryan Comstock, Kristin Follmer, Solange Mecham, Sung Min Kim, Christopher Nefcy, Angela Smith, and CISTO Collaborative John GoreJohn Gore More articles by this author , Erika WolffErika Wolff More articles by this author , Michael NashMichael Nash More articles by this author , Bryan ComstockBryan Comstock More articles by this author , Kristin FollmerKristin Follmer More articles by this author , Solange MechamSolange Mecham More articles by this author , Sung Min KimSung Min Kim More articles by this author , Christopher NefcyChristopher Nefcy More articles by this author , Angela SmithAngela Smith More articles by this author , and CISTO Collaborative More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003223.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Patients with recurrent non-muscle-invasive bladder cancer weigh the risk of cancer progression and loss of a window of potential cure with medical therapy against the risk of morbidity and loss of quality of life (QOL) with radical cystectomy. The pragmatic CISTO Study (NCT03933826) includes the collection of patient-reported outcomes to help future patients make this treatment decision. METHODS: 572 patients will be enrolled and complete baseline and follow up surveys quarterly for up to 4 years. Centralized collection of follow-up surveys utilizes several modalities for contacting participants (email, mail, phone, text) as well as completing the survey (online, paper). Baseline and follow up surveys assess QOL and physical functioning (EORTC QLQ-C30), urinary, sexual, and bowel function (Bladder Cancer Index, BCI), financial distress (Comprehensive Score for Financial Toxicity, COST), anxiety and depression (PROMIS), and generic QOL (EQ5D). Follow up surveys also assess healthcare utilization and decision regret. RESULTS: 337 participants have been enrolled. The completion rate for the primary endpoint of QOL at 12 months is 93%. Among returned surveys, the overall rate of missingness at baseline and 12-months was low (<5%) and there was no evidence of survey fatigue. The BCI had the highest missingness rate (4% and 7%, respectively). The 10 items with the most missingness were in the BCI sexual function domain (8-13% and 11-18%, respectively). CONCLUSIONS: Based on the high rate of survey completion, the CISTO Study will be powered to compare outcomes across a variety of domains, including QOL, urinary function, and anxiety. The missingness of questions relating to sexual function makes it unlikely that this study will yield valid and generalizable results in this specific domain. This, in combination with anecdotal evidence that participants find these questions upsetting, even when optional, and confusing, as there is no place to indicate that the questions do not apply if they are not sexually active, highlights the difficulty in researching this intensely personal outcome. Source of Funding: Research reported in this work was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (PCS-2017C3-9380) © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e100 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information John Gore More articles by this author Erika Wolff More articles by this author Michael Nash More articles by this author Bryan Comstock More articles by this author Kristin Follmer More articles by this author Solange Mecham More articles by this author Sung Min Kim More articles by this author Christopher Nefcy More articles by this author Angela Smith More articles by this author CISTO Collaborative More articles by this author Expand All Advertisement PDF downloadLoading ...